標(biāo)題: Titlebook: Biopatent Law: Patent Strategies and Patent Management; Andreas Hübel,Thilo Schmelcher,Ulrich Storz Book 2012 Ulrich Storz 2012 Biopharmac [打印本頁(yè)] 作者: FLAW 時(shí)間: 2025-3-21 17:32
書目名稱Biopatent Law: Patent Strategies and Patent Management影響因子(影響力)
書目名稱Biopatent Law: Patent Strategies and Patent Management影響因子(影響力)學(xué)科排名
書目名稱Biopatent Law: Patent Strategies and Patent Management網(wǎng)絡(luò)公開度
書目名稱Biopatent Law: Patent Strategies and Patent Management網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biopatent Law: Patent Strategies and Patent Management被引頻次
書目名稱Biopatent Law: Patent Strategies and Patent Management被引頻次學(xué)科排名
書目名稱Biopatent Law: Patent Strategies and Patent Management年度引用
書目名稱Biopatent Law: Patent Strategies and Patent Management年度引用學(xué)科排名
書目名稱Biopatent Law: Patent Strategies and Patent Management讀者反饋
書目名稱Biopatent Law: Patent Strategies and Patent Management讀者反饋學(xué)科排名
作者: 谷物 時(shí)間: 2025-3-21 22:33 作者: MIME 時(shí)間: 2025-3-22 01:20 作者: 古老 時(shí)間: 2025-3-22 04:37
Biopatent Law: Patent Strategies and Patent Management978-3-642-24846-7Series ISSN 2192-9904 Series E-ISSN 2192-9912 作者: FAZE 時(shí)間: 2025-3-22 11:34 作者: chisel 時(shí)間: 2025-3-22 13:33 作者: 手工藝品 時(shí)間: 2025-3-22 18:57
https://doi.org/10.1007/978-3-642-24846-7Biopharmaceutics; Intellectual properties; Invention; Litigation strategies; Patent infringement作者: chiropractor 時(shí)間: 2025-3-23 00:53
https://doi.org/10.1007/978-3-662-46444-1ed requirements. However, unique requirements were established such that the peculiarities of biotechnological inventions can be considered. Nonetheless, it appears that certain specific regulations for obtaining patent protection for a biotechnological invention poses more burden to an applicant th作者: 方舟 時(shí)間: 2025-3-23 02:33
https://doi.org/10.1007/978-3-662-43205-1ategies both from an active viewpoint as claimant and a passive viewpoint as a respondent. Active and passive will be interpreted with respect to an intellectual pro perty rights (IPR) portfolio and it will be interpreted in light of actions performed with respect to an IPR portfolio. Both views hav作者: propose 時(shí)間: 2025-3-23 06:23
Laser Speckle and Related Phenomenad into research and development, their lifetime is restricted. However, due to lengthy authorisation processes for pharmaceutical products, biopharmaceutic innovators cannot exploit the full lifetime of their patents. In order to provide sufficient incentive to develop new drugs, all major countries作者: 搖曳 時(shí)間: 2025-3-23 12:12 作者: encyclopedia 時(shí)間: 2025-3-23 17:34
2192-9904 ed how market exclusivity can be extended as long as possible, which is particularly important for biopharmaceutical drugs, which create high R&D costs..978-3-642-24845-0978-3-642-24846-7Series ISSN 2192-9904 Series E-ISSN 2192-9912 作者: judicial 時(shí)間: 2025-3-23 21:12 作者: 外來 時(shí)間: 2025-3-24 00:41 作者: 說笑 時(shí)間: 2025-3-24 03:14
Book 2012, like supplementary protection certificates and data exclusivity. Here, strategies are discussed how market exclusivity can be extended as long as possible, which is particularly important for biopharmaceutical drugs, which create high R&D costs..作者: 控制 時(shí)間: 2025-3-24 07:16
https://doi.org/10.1007/978-3-662-43205-1e an influence on each other. Even though these perspectives are at first hand seen as independent, typically a claimant will also become a respondent. Also the portfolio situations may change and so—up to a certain point in time—an IPR portfolio may still be shaped to same extent.作者: Absenteeism 時(shí)間: 2025-3-24 10:54
Laser Speckle and Related Phenomenatent lifecycle management strategies, which encompass the strategic filing of subsequent patent applications by the applicant, may help to extend the duration under in which a biopharmaceutic product can be sold under exclusivity.作者: 表否定 時(shí)間: 2025-3-24 17:47
Patent Lifecycle Management, Supplementary Protection Certificates and Data Exclusivity in Biopharmtent lifecycle management strategies, which encompass the strategic filing of subsequent patent applications by the applicant, may help to extend the duration under in which a biopharmaceutic product can be sold under exclusivity.作者: antiandrogen 時(shí)間: 2025-3-24 19:42 作者: 男生戴手銬 時(shí)間: 2025-3-24 23:54
6樓作者: 畫布 時(shí)間: 2025-3-25 03:37
6樓作者: 嚴(yán)峻考驗(yàn) 時(shí)間: 2025-3-25 08:46
7樓作者: habile 時(shí)間: 2025-3-25 13:12
7樓作者: 項(xiàng)目 時(shí)間: 2025-3-25 17:19
7樓作者: 抵押貸款 時(shí)間: 2025-3-25 21:53
7樓作者: Motilin 時(shí)間: 2025-3-26 00:21
8樓作者: 遭受 時(shí)間: 2025-3-26 08:09
8樓作者: 制造 時(shí)間: 2025-3-26 11:48
8樓作者: defile 時(shí)間: 2025-3-26 13:25
9樓作者: 壕溝 時(shí)間: 2025-3-26 19:19
9樓作者: 種子 時(shí)間: 2025-3-26 23:23
9樓作者: 向前變橢圓 時(shí)間: 2025-3-27 01:45
9樓作者: defeatist 時(shí)間: 2025-3-27 07:19
10樓作者: CHAFE 時(shí)間: 2025-3-27 13:07
10樓作者: STYX 時(shí)間: 2025-3-27 15:24
10樓作者: hankering 時(shí)間: 2025-3-27 19:33
10樓
